Literature DB >> 34694418

Risk Factors and Rate of Recurrence after Mohs Surgery in Basal Cell and Squamous Cell Carcinomas: A Nationwide Prospective Cohort (REGESMOHS, Spanish Registry of Mohs Surgery).

Alejandra Tomás-Velázquez1, Onofre Sanmartin-Jiménez, Joan R Garcés, Manuel A Rodríguez-Prieto, Verónica Ruiz-Salas, Esther De Eusebio-Murillo, Román Miñano-Medrano, Begoña Escutia-Muñoz, Ángeles Flórez-Menéndez, Juan L Artola-Igarza, Alberto Alfaro-Rubio, Pilar Gil, Yolanda Delgado-Jiménez, Julia M Sanchez-Schmidt, Irati Allende-Markixana, María L Alonso-Pacheco, Beatriz García-Bracamonte, Pablo De la Cueva-Dobao, Raquel Navarro-Tejedor, Cristina Ciudad-Blanco, Lucía Carnero-González, Hugo Vázquez-Veiga, Natividad Cano-Martínez, Eva Vilarrasa-Rull, Pedro Sanchez-Sambucety, José L López-Estebaranz, Rafael Botella-Estrada, Beatriz Gonzalez-Sixto, Antonio Martorell-Calatayud, Victoriano Morales-Gordillo, Agustí Toll-Abelló, Izascun Ocerin-Guerra, Matías Mayor-Arenal, Ricardo Suárez-Fernández, Laura Sainz-Gaspar, Miguel A Descalzo, Ignacio García-Doval, Pedro Redondo.   

Abstract

Randomized studies to assess the efficacy of Mohs micrographic surgery in basal cell and squamous cell carcinomas are limited by methodological and ethical issues and a lack of long follow-up periods. This study presents the "real-life" results of a nationwide 7-years cohort on basal cell carcinoma and squamous cell carcinoma treated with Mohs micrographic surgery. A prospective cohort was conducted in 22 Spanish centres (from July 2013 to February 2020) and a multivariate analysis, including characteristics of patients, tumours, surgeries and follow-up, was performed. A total of 4,402 patients followed up for 12,111 patient-years for basal cell carcinoma, and 371 patients with 915 patient-years of follow-up for squamous cell carcinoma were recruited. Risk factors for recurrence included age, non-primary tumours and more stages or unfinished surgeries for both tumours, and immunosuppression for squamous cell carcinoma. Incidence rates of recurrence were 1.3 per 100 person-years for basal cell carcinoma (95% confidence interval 1.1-1.5) and 4.5 for squamous cell carcinoma (95% confidence interval 3.3-6.1), being constant over time (0-5 years). In conclusion, follow-up strategies should be equally intense for at least the first 5 years, with special attention paid to squamous cell carcinoma (especially in immunosuppressed patients), elderly patients, non-primary tumours, and those procedures requiring more stages, or unfinished surgeries.

Entities:  

Mesh:

Year:  2021        PMID: 34694418      PMCID: PMC9455311          DOI: 10.2340/actadv.v101.544

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   3.875


  34 in total

1.  Basal cell carcinoma treated with Mohs surgery in Australia I. Experience over 10 years.

Authors:  Igal Leibovitch; Shyamala C Huilgol; Dinesh Selva; Shawn Richards; Robert Paver
Journal:  J Am Acad Dermatol       Date:  2005-09       Impact factor: 11.527

2.  Survival of Patients with Cutaneous Squamous Cell Carcinoma: Results of a Prospective Cohort Study.

Authors:  Thomas K Eigentler; Ulrike Leiter; Hans-Martin Häfner; Claus Garbe; Martin Röcken; Helmut Breuninger
Journal:  J Invest Dermatol       Date:  2017-07-21       Impact factor: 8.551

3.  Surgical excision versus Mohs' micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up.

Authors:  Eva van Loo; Klara Mosterd; Gertruud A M Krekels; Marieke H Roozeboom; Judith U Ostertag; Carmen D Dirksen; Peter M Steijlen; H A Martino Neumann; Patty J Nelemans; Nicole W J Kelleners-Smeets
Journal:  Eur J Cancer       Date:  2014-09-25       Impact factor: 9.162

Review 4.  Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines.

Authors:  Ketty Peris; Maria Concetta Fargnoli; Claus Garbe; Roland Kaufmann; Lars Bastholt; Nicole Basset Seguin; Veronique Bataille; Veronique Del Marmol; Reinhard Dummer; Catherine A Harwood; Axel Hauschild; Christoph Höller; Merete Haedersdal; Josep Malvehy; Mark R Middleton; Colin A Morton; Eduardo Nagore; Alexander J Stratigos; Rolf-Markus Szeimies; Luca Tagliaferri; Myrto Trakatelli; Iris Zalaudek; Alexander Eggermont; Jean Jacques Grob
Journal:  Eur J Cancer       Date:  2019-07-06       Impact factor: 9.162

5.  Chemosurgery: my 15 years of experience.

Authors:  P Robins
Journal:  J Dermatol Surg Oncol       Date:  1981-10

6.  Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia II. Perineural invasion.

Authors:  Igal Leibovitch; Shyamala C Huilgol; Dinesh Selva; Dudley Hill; Shawn Richards; Robert Paver
Journal:  J Am Acad Dermatol       Date:  2005-08       Impact factor: 11.527

7.  Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years.

Authors:  Igal Leibovitch; Shyamala C Huilgol; Dinesh Selva; Dudley Hill; Shawn Richards; Robert Paver
Journal:  J Am Acad Dermatol       Date:  2005-08       Impact factor: 11.527

Review 8.  Mohs' micrographic surgery for treatment of basal cell carcinoma of the face--results of a retrospective study and review of the literature.

Authors:  N W J Smeets; D I M Kuijpers; P Nelemans; J U Ostertag; M E J M Verhaegh; G A M Krekels; H A M Neumann
Journal:  Br J Dermatol       Date:  2004-07       Impact factor: 9.302

9.  Chemosurgery for the microscopically controlled excision of cutaneous cancer.

Authors:  F E Mohs
Journal:  Head Neck Surg       Date:  1978 Nov-Dec

10.  Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial.

Authors:  Nicole W J Smeets; Gertruud A M Krekels; Judith U Ostertag; Brigitte A B Essers; Carmen D Dirksen; Fred H M Nieman; H A Martino Neumann
Journal:  Lancet       Date:  2004 Nov 13-19       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.